Navigation Links
Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
Date:2/18/2009

LYON, France, February 18 /PRNewswire-FirstCall/ --

- Global Clinical Study Program Across Dengue Endemic Regions in Latin America and Asia

Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today that its investigational tetravalent dengue vaccine is entering into a pediatric clinical study in Thailand to assess the efficacy of the vaccine in protecting children against dengue, the most widespread tropical disease after malaria. Sanofi Pasteur's tetravalent dengue vaccine candidate is the first to reach this stage of clinical development.

Sanofi Pasteur is collaborating with Mahidol University of Thailand, the Ministry of Public Health, and the Pediatric Dengue Vaccine Initiative (PDVI) to conduct this efficacy study in the province of Ratchaburi.

"Large scale pediatric studies are instrumental for the development of a safe and efficacious dengue vaccine to protect against a disease that primarily affects children," said Dr. Pratap Singhasivanon, Dean of the Faculty of Tropical Medicine, Mahidol University. "We are happy to contribute to an important milestone with the actual start of an efficacy study in Ratchaburi."

The Sanofi Pasteur clinical study program follows guidelines from the Initiative for Vaccine Research (IVR) led by the World Health Organization (WHO), which fosters the global efforts towards dengue vaccine development.

"WHO is committed to the availability of a dengue vaccine that will ultimately benefit children in endemic countries," said Dr. Joachim Hombach, Coordinator Implementation Research for IVR, WHO.

About Sanofi Pasteur dengue vaccine global clinical study program

Sanofi Pasteur started the development of a dengue vaccine in the 90's. Clinical studies with the most advanced tetravalent candidate vaccine started in the 2000's. In a study in the U
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Demand for VScan Dengue Fever Test Kits Increases
10. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
11. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... 17, 2013  Boehringer Ingelheim will contribute to ... the American Thoracic Society International Conference (ATS 2013) ... 17 – 22. Data will highlight ... treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® ... investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) ...
(Date:5/17/2013)... (EURONEXT: SAN and NYSE: SNY ) announced today ... examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), ... primary endpoint assessed the proportion of patients achieving >/=35% ... previous trials, the most common adverse events were anemia, ... at an upcoming medical congress. MF ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
(Date:5/19/2013)... 19, 2013 The legal team at ... in a concerted effort to connect women and families ... control drugs Yaz, Yasmin & Ocella with the legal ... information on the notorious birth control drugs as well ... , Yaz, Yasmin & Ocella were very popular ...
(Date:5/18/2013)... 18, 2013 Daily Gossip issued a press ... review on their page. John Colston, Daily Gossip’s spokesperson, told ... Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan . ... carbs are healthy at a time when nutritionists and fat ... caloric products. , The diet is based on the ...
(Date:5/18/2013)... Also known as bariatric surgery , ... surgery that guarantees patients long-term weight loss. Dr. Naim ... give readers a brief tutorial on this revolutionary weight ... New York City’s Mount Sinai School of Medicine. After ... fellowship in Minimally Invasive Bariatric Surgery. He has also ...
(Date:5/18/2013)... Children who swallow high-powered magnets often need surgery and ... a new study. The researchers, from the Louisiana ... more than 79 percent of children who swallowed very ... procedure, in which a tube containing a camera is ... these cases can be treated through observation or by ...
(Date:5/18/2013)... FL (May 18, 2013) There are significant ... commonly used to diagnose or treat gastrointestinal problems, ... (DDW). , A study by New York ... more objective testing may substantially reduce the cost ... Although GERD is believed to affect nearly 25 ...
Breaking Medicine News(10 mins):Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2
... to keep smoking, experts say , TUESDAY, June 15 (HealthDay News) ... a B vitamin are half as likely as others to develop ... doesn,t mean that smokers should hit the vitamin aisle instead of ... as one amino acid, to fewer cases of lung cancer, it ...
... a unanimous decision, the Florida Advisory Council on Radiation ... Radiation Oncology,s (ASTRO) patient protection plan. , ASTRO,s Board ... of the Society,s patient safety and quality assurance projects, ... January 28-31, 2010. The goal of the plan is ...
... The Sixth Book in ... the 21st Century and Presents the Essence and Secrets of Ancient Teachings of Tao Along ... , ... the newly released sixth book of his best-selling Soul Power Series, Tao I: The Way of ...
... book by researchers at Oregon State University uses the snapshot-in-time ... types of animal and plant fossils not just what ... behaved, especially at the moment of death. All kinds ... mating and reproductive instincts, to the behavior of pathogenic microbes ...
... ... calves by kayak and and view them just a few meters from ... is a national park, UNESCO World Heritage Site, and the only calving ... camping, whale watch cruise and van tour of the peninsula,s unique wildlife, ...
... found cases missed by routine screening, researchers say , TUESDAY, ... the methods for early detection of HIV, researchers sought to ... increase the number of cases that could be detected early, ... Nucleic acid tests look for traces of genetic material from ...
Cached Medicine News:Health News:Vitamin B6 Tied to Lowered Lung Cancer Risk 2Health News:Vitamin B6 Tied to Lowered Lung Cancer Risk 3Health News:Florida radiation council endorses ASTRO patient protection plan 2Health News:TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List 2Health News:TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List 3Health News:A new view of fossils: The behavior of ancient life forms 2Health News:Kayak With Whales Argentina Patagonia - From Our Exclusive Beach Camp 2Health News:Gene-Based Detection Method Might Spot HIV Earlier 2
Straight shafts with two point fixation. Tips separated by 3 mm, each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with dull finish....
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
5 mm jaws with teeth provide secure fixation of occular structures....
Straight shafts with fine Pierse type tips. Flat smooth handle with dull finish....
Medicine Products: